A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice

Launched by NOVO NORDISK A/S · Oct 20, 2020

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
• • Diagnosed with type 2 diabetes mellitus
• • The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study
• • Male or female, age above or equal to 18 years at the time of signing informed consent
• • Available HbA1c value less than or equal to 90 days prior to the 'Informed Consent and Treatment Initiation visit' (V1) or HbA1c measurement taken in relation with the 'Informed Consent and Treatment Initiation visit'(V1) if in line with local clinical practice
• • Treatment naïve to injectable glucose-lowering drug(s). An exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days
• Exclusion Criteria:
• • Previous participation in this study. Participation is defined as having given informed consent in this study
• • Treatment with any investigational drug within 30 days prior to enrolment into the study
• • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation